Supportive Care in Cancer

, Volume 16, Issue 9, pp 1041–1048 | Cite as

The use and toxicity of steroids in the management of patients with brain metastases

  • Alina Sturdza
  • Barbara-Ann Millar
  • Neelufer Bana
  • Normand Laperriere
  • Gregory Pond
  • Rebecca K. S. Wong
  • Andrea BezjakEmail author
Original Article


Goals of work

To document the use of steroids and frequency of their side effects in patients with brain metastases.

Patients and methods

A survey of oncologists who manage patients with brain metastases was conducted to document steroid prescribing practice in our institution. In addition, a retrospective chart review of 88 patients treated with whole brain radiotherapy (WBRT), identified through the Palliative Radiation Oncology Program database, was conducted for a 6-month period to documents steroid doses prescribed, tapering schedules, and steroid side effects.


Ninety percent of physicians responded to the survey. Forty-five percent routinely used dexamethasone 4 mg qid (16 mg/day). The others determined the dose of steroid according to the presence or absence of neurological symptoms. Sixty percent tapered the patient’s steroids over the 4 weeks following completion of WBRT. The most common side effects noted by physicians were: increased appetite or weight gain (46%), insomnia (24%), gastro-intestinal symptoms (20%). In the retrospective study, dexamethasone 4 mg qid was prescribed to 52% patients prior and during WBRT. Sixty-six percent of patients were instructed to taper dexamethasone after WBRT, but details were not provided. The most frequently documented steroid-related side effects were: increased appetite (32%), proximal muscle weakness (28%), and insomnia (21%).


There is considerable variation in the prescribing practices even within a single institution, with many patients receiving high dose of steroids for considerable periods of time and developing related side effects. Strategies to reduce the amount and length of steroids may result in improved therapeutic ratio; we are currently accruing onto such a trial.


Brain metastases Dexamethasone Steroid use Whole-brain-radiation therapy 


  1. 1.
    Bascuas M, Amares SG, Machuca Munoz MT, Bascuas Asta L (1985) Effect of dexamethasone at the level of cerebral metastases: evaluation by CT and nuclear medicine. Rev Esp Oncol 32:539–542Google Scholar
  2. 2.
    Bezjak A et al (2001) Radiotherapy for brain metastases: defining palliative response. Radiother Oncol 61:71–76PubMedCrossRefGoogle Scholar
  3. 3.
    Bezjak A et al (2002) Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 38:487–496PubMedCrossRefGoogle Scholar
  4. 4.
    Cairncross JG, Kim JH, Posner JB (1980) Radiation therapy for brain metastases. Ann Neurol 7:529–41PubMedCrossRefGoogle Scholar
  5. 5.
    Cairncross JG, Posner JB (1983) The management of brain metastases. In: Walker MD (ed) Oncology of the nervous system. vol. 12. Springer, Verlag, pp 342–377Google Scholar
  6. 6.
    Galicich JH, French LA, Melby JC (1961) Use of dexamethasone in the treatment of cerebral edema associated with brain Tumors. Lancet 81:46Google Scholar
  7. 7.
    Hempen C, Weiss E, Hess CF (2002) Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side effects. Support Care Cancer 10:322–328PubMedCrossRefGoogle Scholar
  8. 8.
    Hoskin PJ, Crow J, Ford HT (1990) The influence of extent and local management on the outcome of radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys 19:111–115PubMedGoogle Scholar
  9. 9.
    Lagerwaard FJ et al (1991) Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43:795–803Google Scholar
  10. 10.
    Mackworth N (1992) Quality of life self-reports from 200 brain tumor patients: comparison with Karnofsky performance scores. J Neuro–Oncol 14:243–253Google Scholar
  11. 11.
    Messer J, Reitman D, Sacks HS, Smith H Jr, Chalmers TC (1983) Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 309:21–24PubMedCrossRefGoogle Scholar
  12. 12.
    Millar BM, Bezjak A, Tsao M, Sturdza A, Laperriere N (2004) Defining the impact and contribution of steroids in patients receiving whole brain irradiation for cerebral metastases. Clin Oncol 16:339–344CrossRefGoogle Scholar
  13. 13.
    Ito U et al (1988) Formation and propagation of brain oedema fluid around human brain metastases: a CT study. Acta Neurochir 90:35–41CrossRefGoogle Scholar
  14. 14.
    Routh AK, Khansur T, Hickman BT, Bass D (1994) Management of brain metastases: past, present and future. South Med J 87:1218–1226PubMedGoogle Scholar
  15. 15.
    Sawaya R (2001) Consideration in the diagnosis and management of brain metastases. Oncol 15:1144–1154Google Scholar
  16. 16.
    Schiff D (2001) Single brain metastases: current treatment options. Neurol 3:89–99Google Scholar
  17. 17.
    Soffietti R (2002) Management of brain metastases. J. Neurol. 249:1357–1369PubMedCrossRefGoogle Scholar
  18. 18.
    Tikhtman AJ, Patchell RA (1994) Brain metastases. In: Morantz RA, Walsh JW (eds) Brain tumors. A comprehensive text. Marcel Dekker, New York, pp 553–566Google Scholar
  19. 19.
    Vecht Ch J, Hovestadt A (1994) Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors. Neurol 44:675–680Google Scholar
  20. 20.
    Weissman DE, Janjan N (1991) Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. J Neuro–Oncol 11:235–239CrossRefGoogle Scholar
  21. 21.
    Wolfson A (1994) The role of steroids in the management of metastatic carcinoma to the brain. Am J Clin Oncol 17:234–238PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Alina Sturdza
    • 1
  • Barbara-Ann Millar
    • 1
  • Neelufer Bana
    • 1
  • Normand Laperriere
    • 1
  • Gregory Pond
    • 2
  • Rebecca K. S. Wong
    • 1
  • Andrea Bezjak
    • 1
    Email author
  1. 1.Department of Radiation Oncology, Princess Margaret HospitalUniversity of TorontoTorontoCanada
  2. 2.Department of Biostatistics, Princess Margaret HospitalUniversity of TorontoTorontoCanada

Personalised recommendations